help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hapangama, D. K.
Right arrow Articles by Baird, D. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hapangama, D. K.
Right arrow Articles by Baird, D. T.
The Journal of Clinical Endocrinology & Metabolism Vol. 87, No. 11 5229-5234
Copyright © 2002 by The Endocrine Society


Original Article

Mifepristone-Induced Vaginal Bleeding Is Associated with Increased Immunostaining for Cyclooxygenase-2 and Decrease in Prostaglandin Dehydrogenase in Luteal Phase Endometrium

Dharani K. Hapangama, Hilary O. D. Critchley, Teresa A. Henderson and David T. Baird

Contraceptive Development Network, Centre for Reproductive Biology, University of Edinburgh, Edinburgh EH3 9ET, United Kingdom

Address all correspondence and requests for reprints to: Professor D. T. Baird, Contraceptive Development Network, Centre for Reproductive Biology, University of Edinburgh, 37 Chalmers Street, Edinburgh EH3 9ET, United Kingdom. E-mail: cdn{at}ed.ac.uk.

Abstract

The mechanism of mifepristone-induced vaginal bleeding and endometrial shedding was investigated in 13 women who took 200 mg mifepristone in the midluteal phase on d 8 after the onset of the urinary LH surge (LH+8). Endometrial biopsies were collected, 6–24 h after mifepristone (group 1, n = 7) or 36–48 h after mifepristone (group 2, n = 6), and compared with those from a control group in the midluteal phase (n = 7). All women reported vaginal bleeding commencing 36–48 h after taking mifepristone. Treatment with mifepristone significantly reduced serum progesterone levels in all women, when compared with the controls (13.2 nM vs. 34.8 nM, P = 0.001). After mifepristone, a significant increase in cyclooxygenase-2 immunoreactivity was apparent at 36–48 h (P = 0.0018), whereas prostaglandin 15 dehydrogenase enzyme-positive immunostaining declined, to be virtually absent by 36–48 h in both glands and in stroma (P < 0.05). There was no change in intensity or distribution of staining for steroid receptors after mifepristone. The changes in immunostaining for cyclooxygenase-2 and prostaglandin 15 dehydrogenase strongly support the hypothesis that an increase in the local concentration of prostaglandins in the endometrium is involved in the mechanism of bleeding induced by mifepristone in the luteal phase.




This article has been cited by other articles:


Home page
Hum ReprodHome page
D.K. Hapangama, M.A. Turner, J.A. Drury, S. Quenby, A. Hart, M. Maddick, C. Martin-Ruiz, and T. von Zglinicki
Sustained replication in endometrium of women with endometriosis occurs without evoking a DNA damage response
Hum. Reprod., March 1, 2009; 24(3): 687 - 696.
[Abstract] [Full Text] [PDF]


Home page
Reproductive SciencesHome page
H. O. D. Critchley and P. T. K. Saunders
Hormone Receptor Dynamics in a Receptive Human Endometrium
Reproductive Sciences, February 1, 2009; 16(2): 191 - 199.
[Abstract] [PDF]


Home page
Hum ReprodHome page
D.K. Hapangama, M.A. Turner, J.A. Drury, S. Quenby, G. Saretzki, C. Martin-Ruiz, and T. Von Zglinicki
Endometriosis is associated with aberrant endometrial expression of telomerase and increased telomere length
Hum. Reprod., July 1, 2008; 23(7): 1511 - 1519.
[Abstract] [Full Text] [PDF]


Home page
Mol Hum ReprodHome page
R.D. Catalano, H.O. Critchley, O. Heikinheimo, D.T. Baird, D. Hapangama, J.R.A. Sherwin, D.S. Charnock-Jones, S.K. Smith, and A.M. Sharkey
Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium
Mol. Hum. Reprod., September 1, 2007; 13(9): 641 - 654.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
N. Narvekar, H. O.D. Critchley, L. Cheng, and D. T. Baird
Mifepristone-induced amenorrhoea is associated with an increase in microvessel density and glucocorticoid receptor and a decrease in stromal vascular endothelial growth factor
Hum. Reprod., September 1, 2006; 21(9): 2312 - 2318.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M. Vaisanen-Tommiska, R. Butzow, O. Ylikorkala, and T. S. Mikkola
Mifepristone-induced nitric oxide release and expression of nitric oxide synthases in the human cervix during early pregnancy
Hum. Reprod., August 1, 2006; 21(8): 2180 - 2184.
[Abstract] [Full Text] [PDF]


Home page
ReproductionHome page
M. Parent, E. Madore, L. A MacLaren, and M. A Fortier
15-Hydroxyprostaglandin dehydrogenase in the bovine endometrium during the oestrous cycle and early pregnancy.
Reproduction, March 1, 2006; 131(3): 573 - 582.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
K. L. Terry, I. De Vivo, L. Titus-Ernstoff, P. M. Sluss, and D. W. Cramer
Genetic Variation in the Progesterone Receptor Gene and Ovarian Cancer Risk
Am. J. Epidemiol., March 1, 2005; 161(5): 442 - 451.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2002 by The Endocrine Society